2015 Lectureship on Cardiovascular Disease

Group Photo Of Professional Colleagues Working Together In Clinical Analysis Laboratory
Clinical Chemist Working
Clinical Chemist Group
Clinical Chemist in Lab
Clinical Chemist in Lab
Clinical Chemist Group
Clinical Chemist Working on Computer
Clinical Chemist in Lab

CSCC Webinar Lectureship on Cardiovascular Disease

Thursday February 26, 2015

08:30 BC/09:30 AB & SK/10:30 MB/11:30 ON & QC/12:30 NS & NB/13:00 NL

Sponsored by

Alere

 

The Canadian Perspective on the

ACC/AHA Dyslipidemia Guidelines

Speaker:

Dr. Todd Anderson

Chair, CCS Dyslipidemia Guidlines Committee
Director, Libin Cardiovascular Institute
Department Head, Cardiac Services
Cumming School of Medicine, University of Calgary

 Registration Form

There is no charge to attend this lecture but it is necessary to register

The lecture will present the Canadian perspective on the ACC/AHA Dyslipidemia guidelines published in 2013. It will compare and contrast the CCS Dyslipidemia guidelines with both the American and European standards. The talk will focus on the topics of risk evaluation, eligibility for therapy and the concept of targets of treatment. I will also discuss chronic kidney disease, fasting vs non-fasting levels as well as the use of secondary biomarker testing. In opinion of the CCS Dyslipidemia panel was that the Canadians standards would not be adjusted in light of the ACC/AHA guidelines but an updated CCS guideline will be developed in 2015.

At the conclusion of this session, participants will be able to:

1)  understand the difference between the current Canadian dyslipidemia guidelines and those introduction in the US last year.
2)  understand the crucial importance of risk determination to guide the need for cholesterol lowering medications.
3)  understand high risk features including chronic kidney disease where statin therapy should be offered to all subjects.